Type 2 diabetes
Janssen-Cilag Ltd are the UK marketing authorisation holder.
Invokana® tablets (canagliflozin hemihydrate)
This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.
We own and maintain the following websites:
Information for patients receiving Invokana
Date of preparation: November 2018 UK/CORP-18046